The FDA has awarded breakthrough device designation to two generative AI systems designed to interpret chest X-rays and automatically draft radiology reports. This designation, reserved for technologies with the potential to improve patient outcomes, fast-tracks regulatory review and development.
The devices, developed by Cognita and Aidoc, represent a growing push to integrate generative AI into medical imaging. By automating report drafting, these tools could reduce radiologist burnout and speed diagnosis, particularly in underserved areas where specialist shortages are acute.
While exact performance data were not disclosed, the breakthrough designation indicates the FDA viewed these systems as offering significant advantages over existing options. The agency's decision underscores its openness to novel AI applications in healthcare, though it does not guarantee eventual market clearance.
The designation may accelerate clinical deployment, but questions remain about accuracy, liability, and how these tools will integrate into existing workflows. Radiologists have expressed caution about over-reliance on AI-generated reports without human oversight.
Counterargument: Critics argue that generative AI in radiology risks introducing errors or biases, and that breakthrough designation should not substitute for rigorous, real-world validation before widespread use.